AI trial design: Phesi vs QuantHealth vs Unlearn

Choose what to model before the protocol is fixed

Clinical-development teams can use AI to examine a study before committing to its design. Phesi Trial Accelerator, QuantHealth Clinical Trial Simulation, and Unlearn Clinical Trial Design address different uncertainties: protocol burden, expected outcomes, and the evidence behind design tradeoffs. This comparison concerns study planning by sponsors and research teams. The table links to current product profiles and documented commercial scope.

Phesi Trial Accelerator

Phesi Trial Accelerator connects patient characteristics with protocol design and operational feasibility. Its Patient View creates a Digital Patient Profile using factors such as comorbidities, demographics, medications, and eligibility values. Trial Performance, Country Performance, and Investigator Site views help model enrollment and compare where a study can be executed. The September 2026 Protocol Complexity module adds a document-centered workflow: agents extract protocol information, a second model checks that extraction, and a transparent rule-based engine scores complexity across five domains. Findings can concern patient burden, investigator workload, endpoints, eligibility, or operations, with supporting evidence and recommendations. Users accept or dismiss findings and can model the effect of a change before adopting it. Phesi suits a team that needs protocol content and feasibility evidence in one planning process. The distinction between agent-assisted extraction and rule-based scoring is meaningful; the complexity number is not simply a generative model’s opinion about a protocol.

QuantHealth Clinical Trial Simulation

QuantHealth Clinical Trial Simulation focuses on modeling how a population may respond to an investigational therapy. Its platform connects biomedical, clinical, and epidemiological information to virtual trial scenarios. Sponsors can vary inclusion and exclusion criteria, treatment regimen, combination, dose, arm size, comparators, and endpoints, then examine predicted outcomes. Enrollment prediction connects protocol cohorts with site-level data, while market forecasting compares the size of relevant populations across geographies. This gives QuantHealth a particular role when the central planning question is how a design change may affect the treatment signal and the population available to study. Its evidence portfolio includes simulations and prospective examples, but those vendor results do not establish the outcome of a new protocol. QuantHealth suits clinical-development teams exploring several plausible designs before allocating trial resources. It provides a simulation-based decision input rather than a replacement for observing outcomes in the actual clinical study.

Unlearn Clinical Trial Design

Unlearn Clinical Trial Design brings together Trial Planning and Simulations with the option to design using AI digital twins. The current planning offer structures precedent into sourced parameters, tests population and endpoint assumptions against the proposed criteria, and compares sample-size and comparator scenarios. Solution Scientists work with the sponsor team, making the engagement broader than a protocol upload followed by an unexplained recommendation. Unlearn’s digital twins are forecasts of an individual participant’s outcomes, generated from baseline data with disease-specific models trained on historical patient information. Design teams can use those forecasts to examine power and sample-size tradeoffs, including designs with smaller control groups. The vendor also describes custom models and flexible deployment for suitable sponsors. Unlearn suits teams that want evidence-linked scenarios and a digital-twin statistical approach. Its cited method qualification has a defined context; it should not be interpreted as blanket regulatory approval of every model, endpoint, or study design.

Protocol burden versus predicted response

Phesi is particularly explicit about making a proposed protocol’s complexity visible and linking it with patient, site, and country feasibility. QuantHealth puts drug-patient response and alternative arm designs at the center of simulation. Unlearn connects sourced design assumptions with digital-twin approaches to sample size and power. A team worried about excessive procedures or narrow criteria has a direct starting point in Phesi’s complexity workflow. A team comparing dose, regimen, or comparator scenarios may find QuantHealth’s outcome modeling more aligned. A team considering how baseline-driven forecasts could strengthen its statistical design should examine Unlearn. These are complementary kinds of planning evidence, rather than one interchangeable protocol-writing feature.

Different meanings of patient models

Phesi’s Digital Patient Profile summarizes the relevant population and supports design and execution choices. QuantHealth simulates drug-patient response across a virtual population and connects those choices to recruitment and market cohorts. Unlearn’s digital twin forecasts an individual’s outcomes under control or standard-of-care conditions using a disease-specific model. Those distinctions prevent an unhelpful comparison in which every patient representation is called the same digital twin. Phesi helps characterize whom and where to study; QuantHealth explores predicted outcomes under alternative clinical scenarios; Unlearn links prognostic forecasts with design and analysis. The appropriate choice follows the unanswered question in the development program.

Compare the study engagement and model scope

Numeric fees and billing intervals for these offers remain unconfirmed. Phesi describes a demo-led SaaS platform, QuantHealth uses enterprise meeting enquiries, and Unlearn offers a scientific partnership around study design. Compare the indication and endpoint coverage, scenario access, data inputs, user access, and included scientific work. Phesi’s Protocol Complexity entitlement, QuantHealth’s simulation scope, and Unlearn’s model and deployment options can change the engagement substantially. Published cost-saving examples describe particular analyses or studies; they are not prices for purchasing the platform.

Which should you choose?

Choose Phesi for protocol complexity and operational feasibility, QuantHealth for drug-patient outcome scenarios, and Unlearn for evidence-linked planning with disease-specific digital twins. Match the product to the design uncertainty your clinical-development team needs to resolve.